As DGAT1 has been mooted as a clinical target for combating obesity, several potent and selective small-molecule inhibitors are already available for repurposing (DeVita and Pinto, 2013). The gene discussed is DGAT1; the disease is obesity due to melanocortin 4 receptor deficiency.